About Glythera
Creating a new generation of biological therapeutics through advanced
glycosylation technologies
Glythera Limited is a young spin-out biotechnology company from the University of Bath with core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to biological therapeutics.
Glythera successfully raised its first round of investment in 2008, with research operations being conducted in dedicated laboratories situated on the campus of the University of Bath.
Glythera's core technologies include:
PermaLinkTM
For the selective and stable functionalisation of protein and peptide based therapeutics.
PermaCarbTM
Maximising the in vivo benefits of your glycosylated therapeutics with a range of degredation resistant glycan analogues.
Our unique approach enables the stable attachment of PermaCarbTM's using PermaLinkTM technology to create drugs with unprecedented biological stability, bioavailability and therapeutic efficacy.
Creating a new generation of biological therapeutics through advanced
glycosylation technologiesGlythera Limited is a young spin-out biotechnology company from the University of Bath with core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to biological therapeutics.
Glythera successfully raised its first round of investment in 2008, with research operations being conducted in dedicated laboratories situated on the campus of the University of Bath.
Glythera's core technologies include:
PermaLinkTMFor the selective and stable functionalisation of protein and peptide based therapeutics.
PermaCarbTMMaximising the in vivo benefits of your glycosylated therapeutics with a range of degredation resistant glycan analogues.
Our unique approach enables the stable attachment of PermaCarbTM's using PermaLinkTM technology to create drugs with unprecedented biological stability, bioavailability and therapeutic efficacy.